EGFR and neoplasm: This is based on the fact that targeted therapies are available for these patients (although not in the neoadjuvant setting [14–16]), and that ALK‐/EGFR‐altered tumours have been shown to have a poor response to IO therapy, leading to their exclusion from the CheckMate 816 trial [5, 17].